StockNews.com downgraded shares of Corbus Pharmaceuticals (NASDAQ:CRBP – Free Report) from a hold rating to a sell rating in a research report released on Saturday. Other research analysts have also recently issued reports about the company. Oppenheimer boosted their price target on Corbus Pharmaceuticals from $58.00 to $60.00 and gave the stock an outperform rating […]